DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Public ClinicalTrials.gov record NCT06805305. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination With Standard of Care for Newly Diagnosed Adult Glioblastoma
Study identification
- NCT ID
- NCT06805305
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Diakonos Oncology Corporation
- Industry
- Enrollment
- 180 participants
Conditions and interventions
Conditions
Interventions
- DOC1021 Biological
- SOC cranial radiation Radiation
- Temodar (Temozolomide) Drug
- Tumor resection Procedure
Biological · Radiation · Drug + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 16, 2025
- Primary completion
- Feb 28, 2030
- Completion
- Feb 29, 2032
- Last update posted
- Apr 21, 2026
2025 – 2032
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | Recruiting |
| City of Hope | Duarte | California | 91010 | Recruiting |
| HOAG | Newport Beach | California | 92663 | Recruiting |
| Baptist MD Anderson Cancer Center | Jacksonville | Florida | 32207 | Recruiting |
| Cooper University Health Care | Camden | New Jersey | 08103 | Recruiting |
| Rutgers Cancer Institute | New Brunswick | New Jersey | 08901 | Recruiting |
| Atlantic Health | Summit | New Jersey | 07901 | Recruiting |
| Lenox Hill Hospital | New York | New York | 10075 | Recruiting |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | 27599 | Recruiting |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27157 | Recruiting |
| The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | Recruiting |
| UPMC Presbyterian Hospital | Pittsburgh | Pennsylvania | 15213 | Recruiting |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37203 | Recruiting |
| UTHealth Houston | Houston | Texas | 77030 | Recruiting |
| Baylor College of Medicine | Houston | Texas | 77057 | Recruiting |
| The University of Texas Health Science Center at San Antonio | San Antonio | Texas | 78229 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06805305, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 21, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06805305 live on ClinicalTrials.gov.